Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 Positive ...

In this Q&A, Beowolff Capital CEO Andrew Wolff explains why he believes the future of the art market lies in transparency, data and A.I.-powered collaboration. He outlines how integrating ...

Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -- Reported highly ...

Even established businesses with substantial IT budgets make critical backup mistakes that can cost millions in lost data and ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced publication in The ...

Q2 2026 Earnings Call Transcript November 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is ...

"Public and private markets are converging, but the data infrastructure hasn't kept pace," said Nicholas Fusco, CEO of PM Insights. "We're not just aggregating data; we're revealing the economic ...

Cogent Biosciences, Inc. earns a Strong Buy rating due to positive phase 3 PEAK results for bezuclastinib + Sunitinib. Read ...

Compare the best business ISPs of 2025. Explore prices and speeds from AT&T, Spectrum, Verizon, Cox and Comcast to find the best fit for you.

Revenues: Revenue for the three months ended September 30, 2025 was $3.7 million, compared to $2.3 million in the same period in 2024. The increase of $1.4 million in revenue resulted from a $1.5 ...

Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo ...